IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
2023年10月6日 - 9:30PM
IMUNON
, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
non-viral DNA-mediated immunotherapy and next-generation vaccines,
announces the appointment of Patrick Ott, M.D., Ph.D. to the
Company’s scientific advisory board.
Dr. Ott is the Clinical Director of the Melanoma
Disease Center and the Director, Clinical Sciences, of the Center
for Immuno-Oncology at the Dana-Farber Cancer Institute. He joins
current scientific advisory board members Dan H. Barouch, M.D.,
Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W.
Shiver, Ph.D.
“We are honored that Dr. Ott has agreed to our
scientific advisory board and believe that he will offer invaluable
guidance as we further develop our technologies and advance our
pipeline,” said Dr. Corinne Le Goff, president and chief executive
officer of IMUNON. “His work with neoantigen vaccines should be
particularly relevant as we advance our FixPlas™ and IndiPlas™
modalities into off the shelf and personalized cancer therapeutics.
Preclinical work in melanoma is already underway.”
Dr. Ott serves as an attending physician in the
Department of Medicine at Brigham and Women's Hospital and is an
Associate Professor at Harvard Medical School. He received his M.D.
and Ph.D. degrees from Ludwig Maximilians University of Munich and
completed his post-doctoral training in immunology and his
residency in Medicine at Case Western Reserve University. After a
fellowship in hematology-oncology and four years on the faculty at
New York University, he joined Dana-Farber in 2012.
He is a clinical investigator and a member of
the clinical trials program at Dana-Farber/Harvard Cancer Center,
where he designs and conducts Phase 1 immunotherapy trials for
patients with a range of tumors including melanoma. His primary
research interests are in the development of innovative tumor
vaccine approaches. Dr. Ott has been Principal Investigator of a
first-in-human clinical trial testing a personalized vaccine
(NeoVax) in patients with melanoma. He has served as Principal
Investigator and co-investigator on more than 30 treatment trials,
including for pembrolizumab and nivolumab in advanced melanoma,
small cell lung cancer and other cancers. This work has resulted in
numerous high-impact publications, including Nature, Nature
Medicine, Cell, Cancer Cell and the Journal of Clinical Oncology.
He has authored more than 160 peer-reviewed articles.
About IMUNON
IMUNON is a fully integrated, clinical-stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlas®,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine®, is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas®, concerns the application of our DNA technology
to produce universal cancer vaccines, also called tumor associated
antigen cancer vaccines. The fourth modality, IndiPlas®, is in the
discovery phase and will focus on the development of personalized
cancer vaccines, or neoepitope cancer vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine (IMNN-101) and a treatment for the LASSA
virus (IMNN-102). The Company has also initiated preclinical work
to develop a Trp2 tumor associated antigen cancer vaccine in
melanoma (IMNN-201). We will continue to leverage these modalities
and to advance the technological frontier of plasmid DNA to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024